Sanwa and Kowa's DPP-4 licensing deal goes global
This article was originally published in Scrip
Executive Summary
Sanwa Kagaku Kenkyushohas granted fellow Japanese firm Kowaexclusive development and marketing rights to its antidiabetic DPP-4 inhibitor, SK-0403, in all markets worldwide excluding South Korea, China and Taiwan. The agreement extends an August co-development and co-commercialisation alliance for Japan, where SK-0403 is in Phase II trials. Sanwa will receive undisclosed upfront, milestone and royalty payments. Kowa recently extended its US marketing capability through the acquisition of ProEthic Pharmaceuticals in August (Scrip Online, August 5th, 2008).
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.